Actual malignancy risk of either operated or non-operated presumed mucinous cystic neoplasms of the pancreas under surveillance.

Published on May 31, 2021in British Journal of Surgery5.676
· DOI :10.1093/BJS/ZNAB131
Giovanni Marchegiani29
Estimated H-index: 29
(University of Verona),
Stefano Andrianello16
Estimated H-index: 16
(University of Verona)
+ 10 AuthorsRoberto Salvia52
Estimated H-index: 52
(University of Verona)
Sources
Abstract
BACKGROUND Despite the low malignant potential of pancreatic mucinous cystic neoplasms (MCNs), surgery is still performed. The aim of this pragmatic study was to assess the outcome of surgery and surveillance for patients presenting with a presumed MCN at the first evaluation. METHODS Data for patients with a presumed MCN observed from 2000 to 2016 at the Verona Pancreas Institute and San Raffaele Hospital were extracted from prospective databases. The endpoints were risk of malignancy at pathology and rate of misdiagnosis for the surgical series, expressed as an odds ratio (OR) with 95 per cent confidence interval, and disease-specific survival (DSS) for the surveillance cohort investigated by the Kaplan-Meier method. RESULTS A total of 424 patients were identified. In the surgical series (229 patients), the rate of misdiagnosis was 19.2 per cent. The rate of malignant MCNs was 10.9 per cent (25 patients). The overall rate of malignancy, including misdiagnoses, was 11.3 per cent (26 patients). Predictors of malignancy were mural nodules (OR 27.75, 95 per cent c.i. 4.44-173.61; P < 0.001), size at least 50 mm (OR 13.39, 2.01 to 89.47; P = 0.007), and carbohydrate antigen 19.9 level (OR 3.98, 1.19 to 13.30; P = 0.025). In the absence of mural nodules and enhancing walls, none of the resected presumed MCNs smaller than 50 mm were malignant. Only patients with high-risk stigmata undergoing surgery experienced a significantly reduced 5-year DSS compared with all other patients (88 versus 100 per cent; P = 0.031). CONCLUSION Presumed MCNs with mural nodules, enhancing walls or cysts of 50 mm or larger should be considered for upfront surgical resection owing to the high risk of malignancy. In the absence of these features, the incidence of malignancy is negligible, favouring surveillance in selected patients given the low risk of malignancy and the high rate of misdiagnosis. GRAPHICAL ABSTRACT Pancreatic mucinous cystic neoplasms (MCNs) are well known preneoplastic lesions. Despite the low rate of cancer, lesions without radiological features of malignancy are resected systematically. In the absence of mural nodules, enhancing walls or cyst size 50 mm or more, the incidence of malignancy is negligible. Given the high risk of misdiagnosis, in the absence of such radiological features, surveillance of presumed MCNs seems safer.
📖 Papers frequently viewed together
6 Authors (Jae Woo Park, ..., Sun Whe Kim)
62 Citations
16 Citations
21 Citations
References34
Newest
#1Marco Del ChiaroH-Index: 31
#2Ross Beckman (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 2
Last. Christopher L. WolfgangH-Index: 102
view all 19 authors...
MiniThis retrospective analysis of 901 patients who underwent pancreatic resection for IPMN shows significant risk of malignancy associated with main duct dilatation greater than 5 mm. While previous studies and guidelines have focused on a 10 mm cutoff for criteria for resection, we provide evidenc
32 CitationsSource
#1Giovanni Marchegiani (University of Verona)H-Index: 29
#2Stefano Andrianello (University of Verona)H-Index: 16
Last. Roberto Salvia (University of Verona)H-Index: 52
view all 10 authors...
OBJECTIVES:The management of small and incidental branch duct intraductal papillary mucinous neoplasms (BD-IPMNs) still is of concern. The aim is assessing the safety of a surveillance protocol through the evaluation of their progression to malignancy.METHODS:All presumed BD-IPMNs observed from 2000
20 CitationsSource
10 CitationsSource
#1Marco Del ChiaroH-Index: 31
#2Marc G. Besselink (UniSR: Vita-Salute San Raffaele University)H-Index: 84
Last. L. WustenH-Index: 1
view all 89 authors...
Evidence-based guidelines on the management of pancreatic cystic neoplasms (PCN) are lacking. This guideline is a joint initiative of the European Study Group on Cystic Tumours of the Pancreas, United European Gastroenterology, European Pancreatic Club, European-African Hepato-Pancreato-Biliary Association, European Digestive Surgery, and the European Society of Gastrointestinal Endoscopy. It replaces the 2013 European consensus statement guidelines on PCN. European and non-European experts perf...
376 CitationsSource
#1Margaret G. Keane (UCL: University College London)H-Index: 13
#2A. Shamali (University of Southampton)H-Index: 8
Last. M Del Chiaro (Karolinska University Hospital)H-Index: 9
view all 16 authors...
BACKGROUND: Pancreatic mucinous cystic neoplasms (MCNs) are rare mucin-producing cystic tumours defined by the presence of ovarian-type stroma. MCNs have a malignant potential and thus surgery is frequently performed. The aim of this cohort study was to define better the criteria for surgical resection in patients with MCN. METHODS: This multicentre retrospective study included all resected MCNs between 2003 and 2015 in participating centres. Lesions without ovarian-type stroma were excluded. Pa...
16 CitationsSource
#1Youngmin Han (Seoul National University Hospital)H-Index: 10
#2Hongeun Lee (Seoul National University Hospital)H-Index: 5
Last. Jin-Young Jang (Seoul National University Hospital)H-Index: 54
view all 10 authors...
Backgrounds & Aims Most guidelines for management of patients with intraductal papillary mucinous neoplasms (IPMN) vary in proposed surveillance intervals and durations—these are usually determined based on expert opinions rather than substantial evidence. The progression of and optimal surveillance intervals for branch-duct IPMNs (BD-IPMN) has not been widely studied. We evaluated the progression of BD-IPMN under surveillance at a single center, and determined optimal follow-up intervals and du...
54 CitationsSource
#1Eizaburo Ohno (Nagoya University)H-Index: 21
#2Yoshiki Hirooka (Nagoya University)H-Index: 59
Last. Hidemi Goto (Nagoya University)H-Index: 72
view all 15 authors...
Backgroud and Aim To elucidate the natural history of pancreatic cystic lesions (PCLs), including branch-duct intraductal papillary mucinous neoplasm (BD-IPMN), via mid-term follow-up analysis of a multicenter prospective observational study (NSPINAL study). Methods From July 2011 to October 2016, 881 patients with PCLs were enrolled in NSPINAL study, and 664 patients with >12 months of follow-up were analysed. Every patient was asymptomatic, and endoscopic ultrasound (EUS) was performed at the ...
27 CitationsSource
#1Hideki Shibata (Showa University)H-Index: 3
#2Nobuyuki Ohike (Showa University)H-Index: 21
Last. Masafumi Takimoto (Showa University)H-Index: 14
view all 12 authors...
BACKGROUND: Pancreatic and hepatic mucinous cyst neoplasms (MCNs) have a malignant potential, but indolent MCNs are not uncommon. MATERIALS AND METHODS: The pathological and genetic characteristics of resected MCNs (n=15) categorized by the amount of mucin of the lining epithelium were investigated. RESULTS: MCNs were divided into two groups: (i) a rich (r)-MCN group (n=6), in which more than half of the epithelium was lined by abundant mucinous epithelium; and (ii) a poor (p)-MCN group (n=9), w...
10 CitationsSource
#1Saurabh Mukewar (Mayo Clinic)H-Index: 19
#2Nicolò de Pretis (Mayo Clinic)H-Index: 8
Last. Suresh T. Chari (Mayo Clinic)H-Index: 103
view all 13 authors...
Objective Fukuoka consensus guidelines classify pancreatic cystic lesions (PCLs) presumed to be intraductal papillary mucinous neoplasms (IPMNs) into Fukuoka positive (FP) (subgroups of high-risk (HR) and worrisome features (WFs)) and Fukuoka negative (FN) (non-HR feature/WF cysts). We retrospectively estimated 5-year risk of pancreatic cancer (PC) in FN, WF and HR cysts of patients with PCL-IPMN. Design From Mayo Clinic databases, we randomly selected 2000 patients reported to have a PCL; we ex...
59 CitationsSource
#1Masao TanakaH-Index: 105
#2Carlos Fernandez-del Castillo (Harvard University)H-Index: 101
Last. Christopher L. Wolfgang (Johns Hopkins University)H-Index: 102
view all 10 authors...
Abstract The management of intraductal papillary mucinous neoplasm (IPMN) continues to evolve. In particular, the indications for resection of branch duct IPMN have changed from early resection to more deliberate observation as proposed by the international consensus guidelines of 2006 and 2012. Another guideline proposed by the American Gastroenterological Association in 2015 restricted indications for surgery more stringently and recommended physicians to stop surveillance if no significant ch...
565 CitationsSource
Cited By0
Newest
#1Rebecca C. Grossman (Buckinghamshire Healthcare NHS Trust)H-Index: 5
#1Rebecca Grossman (Buckinghamshire Healthcare NHS Trust)H-Index: 11
Last. Rebecca C. Grossman (Buckinghamshire Healthcare NHS Trust)H-Index: 4
view all 1 authors...
3 CitationsSource